Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. The drug, which the French pharma giant acquired through a $3.7 billion buyout of ...
SAN DIEGO — Phase 3 data support rilzabrutinib as a potential first-in-class oral Bruton tyrosine kinase (BTK) inhibitor for patients with previously treated immune thrombocytopenia (ITP). In the LUNA ...
Q: My platelets were slightly elevated on my blood test. What can cause this? A: Platelets are part of how our body forms clots to stop bleeding. They are produced in the bone marrow by cells called ...
NEW ORLEANS — Efgartigimod demonstrated clinically significant improvement in platelet counts compared with placebo among adults with primary immune thrombocytopenia, results of the phase 3 ADVANCE IV ...
A panelist discusses how immune thrombocytopenia (ITP) is characterized by isolated low platelet counts due to autoimmune destruction, with classification based on duration (acute, extended, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback